Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of DeathEdward Abraham, William L. Macias, Pierre‐François Laterre et al.|New England Journal of Medicine|2005Cited by 890
Early changes in organ function predict eventual survival in severe sepsis*Mitchell M. Levy, Mark D. Williams, William L. Macias et al.|Critical Care Medicine|2005Cited by 358
Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*Jean‐Louis Vincent, Jonathan Janes, Christopher J. Doig et al.|Critical Care Medicine|2005Cited by 321
Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsisE. Wesley Ely, Gordon R. Bernard, Pierre‐François Laterre et al.|Critical Care Medicine|2003Cited by 283